SBI-115
SBI-115 is a TGR5 (GPCR19) antagonist. SBI-115 decreases hepatic cystogenesis with polycystic liver diseases via inhibiting TGR5[1].
Product Specifications
CAS Number
[882366-16-7]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
G protein-coupled Bile Acid Receptor 1
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
COVID-19-immunoregulation
Field of Research
Others
Assay Protocol
https://www.medchemexpress.com/SBI-115.html
Purity
99.58
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(C1=NC(S(=O)(CC)=O)=NC=C1Cl)OC2=CC=CC(C)=C2
Molecular Formula
C14H13ClN2O4S
Molecular Weight
340.78
Precautions
H302, H315, H319, H335
References & Citations
[1]Masyuk TV, et al. TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling. Hepatology. 2017 Oct; 66 (4) :1197-1218.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
GTR15304870 1 Vial
Lentiviral human MAD2L2 shRNA (UAS) - Lentiviral human MAD2L2 shRNA (UAS) plasmid
Ask
View Details 
